title: Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
abstract: Two patients with scleroderma and recurrent digital ulcers (DUs) were treated with bosentan for 6 months. Treatment was associated with a reduction in the number of new DUs; however, DUs recurred on treatment discontinuation. This case report illustrates the positive response of digital vasculopathy to bosentan and describes the benefits of multiple bosentan treatment courses in these patients.
authors.affiliation: Royal Free Hospital, London, UK.
authors.forename: Tanaka
authors.initials: T
authors.lastname: Ngcozana
authors.forename: Voon
authors.initials: V
authors.lastname: Ong
authors.forename: Christopher Paul
authors.initials: CP
authors.lastname: Denton
mesh_terms: D000328:Adult; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists / Q000008:administration & dosage*; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D012595:Scleroderma, Systemic / Q000150:complications*; D012883:Skin Ulcer / Q000188:drug therapy* / Q000209:etiology; D013449:Sulfonamides / Q000008:administration & dosage*; D014652:Vascular Diseases / Q000188:drug therapy* / Q000209:etiology
chemical_list: D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan